Iovance Biotherapeutics, Inc. (LON:0JDK)

Iovance Biotherapeutics Statistics

Total Valuation

LON:0JDK has a market cap or net worth of GBP 724.88 million. The enterprise value is 536.74 million.

Market Cap	724.88M
Enterprise Value	536.74M

Important Dates

The last earnings date was Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	396.97M
Shares Outstanding	n/a
Shares Change (YoY)	+19.46%
Shares Change (QoQ)	+8.83%
Owned by Insiders (%)	7.38%
Owned by Institutions (%)	48.30%
Float	338.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.89
PB Ratio	1.39
P/TBV Ratio	2.34
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-1.81
EV / Sales	2.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.05

Financial Position

The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.07.

Current Ratio	3.41
Quick Ratio	2.92
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	-0.15
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -53.89% and return on invested capital (ROIC) is -31.99%.

Return on Equity (ROE)	-53.89%
Return on Assets (ROA)	-27.12%
Return on Invested Capital (ROIC)	-31.99%
Return on Capital Employed (ROCE)	-52.79%
Revenue Per Employee	222,316
Profits Per Employee	-353,001
Employee Count	838
Asset Turnover	0.26
Inventory Turnover	4.40

Taxes

Income Tax	-518,526
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -76.56% in the last 52 weeks. The beta is 0.83, so LON:0JDK's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-76.56%
50-Day Moving Average	2.21
200-Day Moving Average	2.89
Relative Strength Index (RSI)	59.11
Average Volume (20 Days)	337,672

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.80

Income Statement

In the last 12 months, LON:0JDK had revenue of GBP 186.30 million and -295.82 million in losses. Loss per share was -0.89.

Revenue	186.30M
Gross Profit	38.55M
Operating Income	-306.00M
Pretax Income	-296.33M
Net Income	-295.82M
EBITDA	-279.56M
EBIT	-306.00M
Loss Per Share	-0.89

Balance Sheet

The company has 223.78 million in cash and 39.05 million in debt, giving a net cash position of 184.73 million.

Cash & Cash Equivalents	223.78M
Total Debt	39.05M
Net Cash	184.73M
Net Cash Per Share	n/a
Equity (Book Value)	522.46M
Book Value Per Share	1.36
Working Capital	225.64M

Cash Flow

In the last 12 months, operating cash flow was -240.40 million and capital expenditures -21.34 million, giving a free cash flow of -261.74 million.

Operating Cash Flow	-240.40M
Capital Expenditures	-21.34M
Free Cash Flow	-261.74M
FCF Per Share	n/a

Margins

Gross margin is 20.69%, with operating and profit margins of -164.25% and -158.78%.

Gross Margin	20.69%
Operating Margin	-164.25%
Pretax Margin	-159.06%
Profit Margin	-158.78%
EBITDA Margin	-150.06%
EBIT Margin	-164.25%
FCF Margin	n/a

Dividends & Yields

LON:0JDK does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-19.46%
Shareholder Yield	-19.46%
Earnings Yield	-40.81%
FCF Yield	-36.11%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0JDK has an Altman Z-Score of -0.5 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.5
Piotroski F-Score	2